Margaret Haney, PhD

Profile Headshot

Overview

Academic Appointments

  • Professor of Neurobiology (in Psychiatry) at CUMC

Administrative Titles

  • Executive Committee, Division on Substance Abuse
  • Director of the Pilot Project Committee: Substance Use Research Center
  • Grand Rounds Committee, Department of Psychiatry
  • Columbia University: Lilly Innovation Fellowship Committee

Dr. Margaret (Meg) Haney is a Professor of Neurobiology (in Psychiatry) at the Columbia University Medical Center, where she is the Director of the Marijuana Research Laboratory and Co-Director of the Substance Use Research Center. Her research focuses on human laboratory models of cannabis and cocaine use disorders and the assessment of novel pharmacologic and immunologic approaches to treat these disorders. Her particular interest is to define the factors that contribute to the daily use of drugs. Her publications to date have largely focused on: (1) the positive and negative reinforcing effects of cocaine and cannabis, (2) the effects of medications on cannabis and cocaine self-administration, (3) predictors of cannabis withdrawal and relapse, (4) the potential medical benefits of different cannabinoids, alone and in combination with opioid medications. 

Dr. Haney's research has been continuously supported by NIDA since 1999. She is internationally recognized for her expertise, particularly regarding cannabis use disorder. She is an author on more than 135 articles in peer-reviewed journals and 11 book chapters, is an Associate Editor for Cannabis and Cannabinoid Research, an advisory editor for Psychopharmacology, a longstanding participant in NIH review groups, and is a fellow in the American College of Neuropsychopharmacology and is on the Board of Directors of the College on Problems of Drug Dependence.

Credentials & Experience

Education & Training

  • PhD, 1992 Tufts University

Research

Research Interests

  • Drug Dependence

Grants

ACUTE EFFECTS OF CANNABIS ON COGNITION AND MOBILITY IN OLDER HIV-INFECTED AND UNINFECTED WOMEN (Federal Gov)

Jul 1 2018 - May 31 2020

NON-METABOLIZED PREGNENOLONE DERIVATIVES:NEW TREATMENT FOR CANNABIS USE DISORDER (Federal Gov)

Sep 1 2016 - Aug 31 2019

SHARED PHARMACOTHERAPEUTIC STRATEGIES FOR CANNABINOID & OPIOID USE DISORDERS (Federal Gov)

Sep 1 2014 - Jun 30 2017

STUDY OF THE EFFECT OF CANNABIS IN HUMANS ON THE PRODUCTION OF PREGNENOLONE AND ENDOCANNABINOIDS (Private)

Jun 7 2016 - Jun 6 2017

STRESS-INDUCED MARIJUANA SELF-ADMINISTRATION: ROLE OF SEX AND OXYTOCIN (Federal Gov)

Sep 15 2013 - Dec 31 2016

MODAFINIL AND DRD4 GENOTYPE IN A HUMAN LABORATORY MODEL OF COCAINE RELAPSE (Federal Gov)

Jul 15 2008 - Jun 30 2014

METABOLIC ADAPTATION AND CHANGES IN CENTRAL NERVOUS SYSTEM CIRCUITRY IN WEIGHT-PERTURBED C57BL/6J MICE (Private)

Jun 16 2008 - Nov 30 2013

MULTI-SITE CONTROLLED TRIAL OF COCAINE VACCINE (6 OF 6) COLUMBIA UNIVERSITY SITE (Federal Gov)

Sep 15 2008 - Jul 31 2013

Selected Publications

  • Haney M, Evins AE. Circumspectives: Does cannabis cause, exacerbate or ameliorate psychiatric disorders? An over-simplified debate discussed. Neuropsychopharmacology 2016, 41: 393-401
  • Haney M, Bedi G, Cooper ZD, Glass A, Vosburg SK, Comer SD, Foltin RW: Predictors of Marijuana Relapse in the Human Laboratory: Robust Impact of Tobacco Cigarette Smoking Status. Biological Psychiatry 2013;73: 242-248
  • Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW: Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biological Psychiatry 2010;67:59-65
  • Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW: Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology 2013;38:1557-1565
  • Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW: Dronabinol and marijuana in HIV+ marijuana smokers: Caloric intake, mood and sleep. JAIDS 2007;32:1391-1403